糖皮质激素受体在泌尿系统恶性肿瘤中的研究进展

doi:10.3760/cma.j.issn.1673-422X.2017.06.019

摘要/Abstract

摘要： 糖皮质激素受体（GR）是类固醇激素核受体超家族成员，可介导糖皮质激素等配体信号，调节靶基因转录，发挥生物学活性。GR在肾癌、膀胱癌和前列腺癌三大泌尿系统恶性肿瘤中均有不同程度表达，能影响肿瘤细胞代谢过程，并与肿瘤发生、发展和预后等环节密切相关。GR为泌尿系统恶性肿瘤的靶向治疗和内分泌治疗提供了重要思路。

关键词: 受体, 糖皮质激素, 肾肿瘤, 膀胱肿瘤, 前列腺肿瘤

Abstract: Glucocorticoid receptor (GR), a member of the steroid receptor superfamily, can mediate the signal pathway of ligands like glucocorticoids, regulate the transcription of target genes, and exert biological activity. GR is expressed in different degrees in three major kinds of urological malignant tumors including renal cancer, bladder cancer and prostate cancer. It also affects the metabolism of tumor cells, and is closely related to the occurrence, development and prognosis of tumors. GR provides an important clue for targeted therapy and endocrine therapy of urological malignant tumors.

Key words: Receptors, glucocorticoid, Kidney neoplasms, Urinary bladder neoplasms, Prostatic neoplasms

周启东，蒋光亮，徐可. 糖皮质激素受体在泌尿系统恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2017, 44(6): 476-.

Zhou Qidong, Jiang Guangliang, Xu Ke. Research progress of glucocorticoid receptor in urological malignant tumors[J]. Journal of International Oncology, 2017, 44(6): 476-.

参考文献

［1］王德杰, 刘兴国, 张东. 糖皮质激素受体的研究进展［J］. 现代生物医学进展, 2010, 10(8): 1592-1594. DOI: 10.13241/j.cnki.pmb.2010.08.001. ［2］ Stechschulte LA, Wuescher L, Marino JS, et al. Glucocorticoid receptor β stimulates Akt1 growth pathway by attenuation of PTEN［J］. J Biol Chem, 2014, 289(25): 17885-17894. DOI: 10.1074/jbc.M113.544072. ［3］ Nicolaides NC, Charmandari E, Chrousos GP, et al. Recent advances in the molecular mechanisms determining tissue sensitivity to glucocorticoids: novel mutations, circadian rhythm and ligandinduced repression of the human glucocorticoid receptor［J］. BMC Endocr Disord, 2014, 14: 71. DOI: 10.1186/147268231471. ［4］ Kassi E, Moutsatsou P. Glucocorticoid receptor signaling and prostate cancer［J］. Cancer Lett, 2011, 302(1): 1-10. DOI: 10.1016/j.canlet.2010.10.020. ［5］ McBeth L, Grabnar M, Selman S, et al. Involvement of the androgen and glucocorticoid receptors in bladder cancer［J］. Int J Endocrinol, 2015, 2015: 384860. DOI: 10.1155/2015/384860. ［6］ Czarnecka AM, Niedzwiedzka M, Porta C, et al. Hormone signaling pathways as treatment targets in renal cell cancer (review)［J］. Int J Oncol, 2016, 48(6): 2221-2235. DOI: 10.3892/ijo.2016.3460. ［7］ Yakirevich E, Matoso A, Sabo E, et al. Expression of the glucocorticoid receptor in renal cell neoplasms: an immunohistochemical and quantitative reverse transcriptase polymerase chain reaction study［J］. Hum Pathol, 2011, 42(11): 1684-1692. DOI: 10.1016/j.humpath.2011.01.014. ［8］ Min KJ, Jang JH, Lee JT, et al. Glucocorticoid receptor antagonist sensitizes TRAILinduced apoptosis in renal carcinoma cells through upregulation of DR5 and downregulation of cFLIP(L) and Bcl2［J］. J Mol Med (Berl), 2012, 90(3): 309-319. DOI: 10.1007/s0010901108218. ［9］ Jang JH, Min KJ, Kim S, et al. RU486 induces proapoptotic endoplasmic reticulum stress through the induction of CHOP expression by enhancing C/EBPδ expression in human renal carcinoma caki cells［J］. J Cell Biochem, 2016, 117(2): 361-369. DOI: 10.1002/jcb.25278. ［10］ Huynh TP, Barwe SP, Lee SJ, et al. Glucocorticoids suppress renal cell carcinoma progression by enhancing Na,KATPase beta1 subunit expression［J］. PLoS One, 2015, 10(4): e122442. DOI: 10.1371/journal.pone.0122442. ［11］ Arai Y, Nonomura N, Nakai Y, et al. The growthinhibitory effects of dexamethasone on renal cell carcinoma in vivo and in vitro［J］. Cancer Invest, 2008, 26(1): 35-40. DOI:10.1080/07357900701638418. ［12］ Zheng Y, Izumi K, Li Y, et al. Contrary regulation of bladder cancer cell proliferation and invasion by dexamethasonemediated glucocorticoid receptor signals［J］. Mol Cancer Ther, 2012, 11(12): 2621-2632. DOI: 10.1158/15357163.MCT120621. ［13］ Ishiguro H, Kawahara T, Zheng Y, et al. Differential regulation of bladder cancer growth by various glucocorticoids: corticosterone and prednisone inhibit cell invasion without promoting cell proliferation or reducing cisplatin cytotoxicity［J］. Cancer Chemother Pharmacol, 2014, 74(2): 249-255. DOI: 10.1007/s0028001424967. ［14］ Zheng Y, Ishiguro H, Ide H, et al. Compound A inhibits bladder cancer growth predominantly via glucocorticoid receptor transrepression［J］. Mol Endocrinol, 2015, 29(10): 1486-1497. DOI: 10.1210/me.20151128. ［15］ Lesovaya E, Yemelyanov A, Kirsanov K, et al. Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies［J］. Cell Cycle, 2013, 12(1): 133-144. DOI: 10.4161/cc.23048. ［16］ Kashiwagi E, Fujita K, Yamaguchi S, et al. Expression of steroid hormone receptors and its prognostic significance in urothelial carcinoma of the upper urinary tract［J］. Cancer Biol Ther, 2016, 17(11): 1188-1196. DOI: 10.1080/15384047.2016.1235667. ［17］ Ishiguro H, Kawahara T, Zheng Y, et al. Reduced glucocorticoid receptor expression predicts bladder tumor recurrence and progression［J］. Am J Clin Pathol, 2014, 142(2): 157-164. DOI: 10.1309/AJCPU8UCEZYG4WTV. ［18］ McBeth L, Nwaneri AC, Grabnar M, et al. Glucocorticoid receptor beta increases migration of human bladder cancer cells［J］. Oncotarget, 2016, 7(19): 27313-27324. DOI: 10.18632/oncotarget.8430. ［19］ Nwaneri AC, McBeth L, Hinds TD Jr. SweetP inhibition of glucocorticoid receptor β as a potential cancer therapy［J］. Cancer Cell Microenviron, 2016, 3(3). pii: e1362. ［20］ Hu J, Chen Q. The role of glucocorticoid receptor in prostate cancer progression: from bench to bedside［J］. Int Urol Nephrol, 2016, 49(3): 369-380. DOI: 10.1007/s1125501614768. ［21］ Isikbay M, Otto K, Kregel S, et al. Glucocorticoid receptor activity contributes to resistance to androgentargeted therapy in prostate cancer［J］. Horm Cancer, 2014, 5(2): 72-89. DOI: 10.1007/s1267201401732. ［22］ Arora VK, Schenkein E, Murali R, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade［J］. Cell, 2013, 155(6): 1309-1322. DOI: 10.1016/j.cell.2013.11.012. ［23］ Xie N, Cheng H, Lin D, et al. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors［J］. Int J Cancer, 2015, 136(4): E27-E38. DOI: 10.1002/ijc.29147. ［24］ Kach J, Conzen SD, Szmulewitz RZ. Targeting the glucocorticoid receptor in breast and prostate cancers［J］. Sci Transl Med, 2015, 7(305): 305ps19. DOI: 10.1126/scitranslmed.aac7531. ［25］ Carreira S, Romanel A, Goodall J, et al. Tumor clone dynamics in lethal prostate cancer［J］. Sci Transl Med, 2014, 6(254): 254ra125. DOI: 10.1126/scitranslmed.3009448.

[1]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[2]	赵鑫, 范学武, 田龙, 胡逸民. 三维超声在前列腺癌图像引导放疗中的应用与评价研究[J]. 国际肿瘤学杂志, 2024, 51(1): 43-49.
[3]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[4]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[5]	陈秋, 王雷, 王明琦, 张梅. 恩沃利单抗联合阿昔替尼治疗肾癌肺转移1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(7): 445-448.
[6]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[7]	张丽, 向卓, 王强, 毕经旺. CAR-T免疫治疗相关的细胞因子释放综合征研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 377-381.
[8]	丁浩, 应劲涛, 付茂勇. CAR-T在食管鳞状细胞癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 231-235.
[9]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[10]	李佳璇, 封颖璐. 糖皮质激素受体在肝癌细胞生长中的作用机制[J]. 国际肿瘤学杂志, 2023, 50(4): 241-243.
[11]	宁婷婷, 胡钦勇, 李倩, 杨鹏程. 奥希替尼与埃克替尼一线治疗EGFR阳性转移性NSCLC临床疗效观察[J]. 国际肿瘤学杂志, 2023, 50(2): 65-70.
[12]	张碧霞, 丁江华. EGFR突变型非小细胞肺癌EGFR-TKI获得性耐药后免疫治疗现状[J]. 国际肿瘤学杂志, 2023, 50(2): 97-101.
[13]	钱伟伟, 徐申, 孔琪. 术前D二聚体在肾嗜酸细胞腺瘤和肾嫌色细胞癌中的鉴别诊断价值[J]. 国际肿瘤学杂志, 2023, 50(10): 614-617.
[14]	于晓鹏, 冯青青, 赵文飞, 赵文文, 魏红梅. 靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用[J]. 国际肿瘤学杂志, 2023, 50(10): 631-635.
[15]	许婷婷, 胡超苏, 李宝生. 抗EGFR单抗治疗局部晚期头颈部鳞状细胞癌临床共识（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(1): 1-11.